Advertisement

Exposome and Diet

  • Jakob Seidelin
  • Johan Burisch
Chapter

Abstract

The underlying etiopathogenic factor for inflammatory bowel disease (IBD) remains unclear. It is generally accepted that IBD results from a complex relationship between genetic susceptibility, environmental factors, and intestinal microbiota, resulting in a self-perpetuating abnormal mucosal immune response. While several environmental factors have been associated with the onset of IBD, to date no specific environmental/microbial causative factors have been identified. Less is known about the influence of the exposome, the sum of all environmental exposures faced by a human being during his life, on the disease course in established IBD. In this chapter we summarize what is known about the influence of environmental exposures such as lifestyle factors, drugs, appendectomy, infections, diet, and external factors such as altitude and pollution. We demonstrate how the influence of the exposome on disease course remains poorly investigated and understood underlining the need for more clinical epidemiological and mechanistic research.

References

  1. 1.
    Wild CP. The exposome: from concept to utility. Int J Epidemiol. 2012;41:24–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Burisch J, Pedersen N, Čuković-Čavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014;63:588–97.PubMedCrossRefGoogle Scholar
  3. 3.
    Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;6736:1–10.Google Scholar
  4. 4.
    Hammer T, Lophaven SN, Nielsen KR, et al. Inflammatory bowel diseases in Faroese-born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development. Aliment Pharmacol Ther. 2017;45:1107–14.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Misra R, Faiz O, Munkholm P, et al. Epidemiology of inflammatory bowel disease in racial and ethnic migrant groups. World J Gastroenterol. 2018;24:424–37.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    To N, Gracie DJ, Ford AC. Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn’s disease. Aliment Pharmacol Ther. 2016;43:549–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Seksik P, Nion-Larmurier I, Sokol H, et al. Effects of light smoking consumption on the clinical course of Crohn’s disease. Inflamm Bowel Dis. 2009;15:734–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001;120:1093–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Höie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007;102:1692–701.CrossRefGoogle Scholar
  10. 10.
    Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507–15.CrossRefGoogle Scholar
  11. 11.
    To N, Ford AC, Gracie DJ. Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. Aliment Pharmacol Ther. 2016;44:117–26.PubMedCrossRefGoogle Scholar
  12. 12.
    Inamdar S, Volfson A, Rosen L, et al. Smoking and early infliximab response in Crohn’s disease: a meta-analysis. J Crohns Colitis. 2015;9:140–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009;15:1105–18.PubMedCrossRefGoogle Scholar
  14. 14.
    Bernstein CN, Singh S, Graff LA, et al. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol. 2010;105:1994–2002.PubMedCrossRefGoogle Scholar
  15. 15.
    Levenstein S, Prantera C, Varvo V, et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol. 2000;95:1213–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Sexton KA, Walker JR, Graff LA, et al. Evidence of bidirectional associations between perceived stress and symptom activity: a prospective longitudinal investigation in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:473–83.PubMedCrossRefGoogle Scholar
  17. 17.
    Loudon CP, Corroll V, Butcher J, et al. The effects of physical exercise on patients with Crohn’s disease. Am J Gastroenterol. 1999;94:697–703.PubMedCrossRefGoogle Scholar
  18. 18.
    Ng V, Millard W, Lebrun C, et al. Low-intensity exercise improves quality of life in patients with Crohn’s disease. Clin J Sport Med. 2007;17:384–8.PubMedGoogle Scholar
  19. 19.
    Jones PD, Kappelman MD, Martin CF, et al. Exercise decreases risk of future active disease in patients with inflammatory bowel disease in remission. Inflamm Bowel Dis. 2015;21:1063–71.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Habib I, Mazulis A, Roginsky G, et al. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: pathophysiology and clinical associations. Inflamm Bowel Dis. 2014;20:2493–502.PubMedCrossRefGoogle Scholar
  21. 21.
    Meyer AM, Ramzan NN, Heigh RI, et al. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 2006;51:168–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000;95:1949–54.PubMedCrossRefGoogle Scholar
  23. 23.
    Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:751–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Bonner GF, Walczak M, Kitchen L, et al. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol. 2000;95:1946–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:196–202.PubMedCrossRefGoogle Scholar
  26. 26.
    Khalili H, Higuchi LM, Ananthakrishnan AN, et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut. 2013;62:1153–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Cosnes J, Carbonnel F, Carrat F, et al. Oral contraceptive use and the clinical course of Crohn’s disease: a prospective cohort study. Gut. 1999;45:218–22.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Sutherland LR, Ramcharan S, Bryant H, et al. Effect of oral contraceptive use on reoperation following surgery for Crohn’s disease. Dig Dis Sci. 1992;37:1377–82.PubMedCrossRefGoogle Scholar
  29. 29.
    Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology. 1998;114:1143–50.PubMedCrossRefGoogle Scholar
  30. 30.
    Khalili H, Granath F, Smedby KE, et al. Association between long-term oral contraceptive use and risk of Crohn’s disease complications in a nationwide study. Gastroenterology. 2016;150:1561–7.e1.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13–20.PubMedCrossRefGoogle Scholar
  32. 32.
    Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:1193–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Crockett SD, Hansen RA, Stürmer T, et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2012;18:1048–56.PubMedCrossRefGoogle Scholar
  34. 34.
    Higgins PD, Khan T, Mapili J, et al. Atorvastatin decreases Seo Index in patients with short duration of disease in ulcerative colitis: a randomized placebo-controlled clinical trial. Gastroenterology. 2006;130:A120.CrossRefGoogle Scholar
  35. 35.
    Grip O, Janciauskiene S, Bredberg A. Use of atorvastatin as an anti-inflammatory treatment in Crohn’s disease. Br J Pharmacol. 2008;155:1085–92.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Naganuma M, Iizuka BE, Torii A, et al. Appendectomy protects against the development of ulcerative colitis and reduces its recurrence: results of a multicenter case-controlled study in Japan. Am J Gastroenterol. 2001;96:1123–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of appendicectomy on the course of ulcerative colitis. Gut. 2002;51:803–7.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Radford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut. 2002;51:808–13.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Hallas J, Gaist D, Vach W, et al. Appendicectomy has no beneficial effect on admission rates in patients with ulcerative colitis. Gut. 2004;53:351–4.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Selby WS, Griffin S, Abraham N, et al. Appendectomy protects against the development of ulcerative colitis but does not affect its course. Am J Gastroenterol. 2002;97:2834–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Myrelid P, Landerholm K, Nordenvall C, et al. Appendectomy and the risk of colectomy in ulcerative colitis: a national cohort study. Am J Gastroenterol. 2017;112:1311–9.CrossRefGoogle Scholar
  42. 42.
    Parian A, Limketkai B, Koh J, et al. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut. 2017;66:1390–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Kaplan GG, Jackson T, Sands BE, et al. The risk of developing Crohn’s disease after an appendectomy: a meta-analysis. Am J Gastroenterol. 2008;103:2925–31.PubMedCrossRefGoogle Scholar
  44. 44.
    Andersson RE, Olaison G, Tysk C, et al. Appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology. 2003;124:40–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Caserta L, de Filippo FR, Riegler G. Relationship between anamnestic evidence of appendectomy and onset and clinical course of Crohn’s disease. Am J Gastroenterol. 2002;97:207–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Sun W, Han X, Wu S, et al. Tonsillectomy and the risk of inflammatory bowel disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:1085–94.PubMedCrossRefGoogle Scholar
  47. 47.
    Gradel KO, Nielsen HL, Schønheyder HC, et al. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology. 2009;137:495–501.PubMedCrossRefGoogle Scholar
  48. 48.
    Jess T, Simonsen J, Nielsen NM, et al. Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. Gut. 2011;60:318–24.PubMedCrossRefGoogle Scholar
  49. 49.
    Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–70.CrossRefGoogle Scholar
  50. 50.
    Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.PubMedCrossRefGoogle Scholar
  51. 51.
    Hanada Y, Khanna S, Loftus EV, et al. Non-clostridium difficile bacterial infections are rare in patients with flares of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2018;16:528–33.PubMedCrossRefGoogle Scholar
  52. 52.
    Van Kruiningen HJ. Where are the weapons of mass destruction − the Mycobacterium paratuberculosis in Crohn’s disease? J Crohns Colitis. 2011;5:638–44.PubMedCrossRefGoogle Scholar
  53. 53.
    Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339–44.PubMedCrossRefGoogle Scholar
  54. 54.
    Saffouri G, Gupta A, Loftus EV, et al. The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease. Scand J Gastroenterol. 2017;52:1240–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Razik R, Rumman A, Bahreini Z, et al. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM study. Am J Gastroenterol. 2016;111:1141–6.PubMedCrossRefGoogle Scholar
  56. 56.
    D’Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol. 2017;23:4986–5003.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345–51.PubMedCrossRefGoogle Scholar
  58. 58.
    Horton HA, Dezfoli S, Berel D, et al. Antibiotics for treatment of Clostridium difficile infection in hospitalized patients with inflammatory bowel disease. Antimicrob Agents Chemother. 2014;58:5054–9.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Cohen S, Martinez-Vinson C, Aloi M, et al. Cytomegalovirus infection in pediatric severe ulcerative colitis-a multicenter study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Pediatr Infect Dis J. 2018;37:197–201.PubMedCrossRefGoogle Scholar
  60. 60.
    Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004;53:1155–60.PubMedCrossRefGoogle Scholar
  61. 61.
    Lv Y-L, Han F-F, Jia Y-J, et al. Is cytomegalovirus infection related to inflammatory bowel disease, especially steroid-resistant inflammatory bowel disease? A meta-analysis. Infect Drug Resist. 2017;10:511–9.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Kopylov U, Papamichael K, Katsanos K, et al. Impact of infliximab and cyclosporine on the risk of colectomy in hospitalized patients with ulcerative colitis complicated by cytomegalovirus-a multicenter retrospective study. Inflamm Bowel Dis. 2017;23:1605–13.PubMedCrossRefGoogle Scholar
  63. 63.
    Shoda R, Matsueda K, Yamato S, et al. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr. 1996;63:741–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology. 2013;145:970–7.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Brotherton CS, Martin CA, Long MD, et al. Avoidance of fiber is associated with greater risk of Crohn’s disease flare in a 6-month period. Clin Gastroenterol Hepatol. 2016;14:1130–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Barnes EL, Nestor M, Onyewadume L, et al. High dietary intake of specific fatty acids increases risk of flares in patients with ulcerative colitis in remission during treatment with aminosalicylates. Clin Gastroenterol Hepatol. 2017;15:1390–6.e1.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Almallah YZ, Richardson S, O’Hanrahan T, et al. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol. 1998;93:804–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Jowett SL, Seal CJ, Pearce MS, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004;53:1479–84.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Chassaing B, Van de Wiele T, De Bodt J, et al. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut. 2017;66:1414–27.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Roberts CL, Rushworth SL, Richman E, et al. Hypothesis: increased consumption of emulsifiers as an explanation for the rising incidence of Crohn’s disease. J Crohns Colitis. 2013;7:338–41.PubMedCrossRefGoogle Scholar
  71. 71.
    Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519:92–6.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Kabbani TA, Koutroubakis IE, Schoen RE, et al. Association of vitamin D level with clinical status in inflammatory bowel disease: a 5-year longitudinal study. Am J Gastroenterol. 2016;111:712–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Simmons JD, Mullighan C, Welsh KI, et al. Vitamin D receptor gene polymorphism: association with Crohn’s disease susceptibility. Gut. 2000;47:211–4.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Gubatan J, Mitsuhashi S, Zenlea T, et al. Low serum vitamin D during remission increases risk of clinical relapse in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2017;15:240–6.e1.PubMedCrossRefGoogle Scholar
  75. 75.
    Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377–83.PubMedCrossRefGoogle Scholar
  76. 76.
    Winter RW, Collins E, Cao B, et al. Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45:653–9.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Hlavaty T, Krajcovicova A, Payer J. Vitamin D therapy in inflammatory bowel diseases: who, in what form, and how much? J Crohns Colitis. 2015;9:198–209.PubMedCrossRefGoogle Scholar
  78. 78.
    Raftery T, O’Sullivan M. Optimal vitamin D levels in Crohn’s disease: a review. Proc Nutr Soc. 2015;74:56–66.PubMedCrossRefGoogle Scholar
  79. 79.
    Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15:39–49.PubMedCrossRefGoogle Scholar
  80. 80.
    McIlroy J, Ianiro G, Mukhopadhya I, et al. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharmacol Ther. 2018;47:26–42.PubMedCrossRefGoogle Scholar
  81. 81.
    Ungaro R, Bernstein CN, Gearry R, et al. Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol. 2014;109:1728–38.PubMedCrossRefGoogle Scholar
  82. 82.
    D’Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology. 2008;135:1123–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102–9.e6.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110–8.e4.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Lewis JD, Chen EZ, Baldassano RN, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. Cell Host Microbe. 2015;18:489–500.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Shaw KA, Bertha M, Hofmekler T, et al. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. Genome Med. 2016;8:75.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Vavricka SR, Rogler G, Maetzler S, et al. High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients. J Crohns Colitis. 2014;8:191–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Ananthakrishnan AN, McGinley EL, Binion DG, et al. Ambient air pollution correlates with hospitalizations for inflammatory bowel disease: an ecologic analysis. Inflamm Bowel Dis. 2011;17:1138–45.PubMedCrossRefGoogle Scholar
  89. 89.
    Forbes JD, Van Domselaar G, Sargent M, et al. Microbiome profiling of drinking water in relation to incidence of inflammatory bowel disease. Can J Microbiol. 2016;62:781–93.PubMedCrossRefGoogle Scholar
  90. 90.
    Aamodt G, Bukholm G, Jahnsen J, et al. The association between water supply and inflammatory bowel disease based on a 1990–1993 cohort study in southeastern Norway. Am J Epidemiol. 2008;168:1065–72.PubMedCrossRefGoogle Scholar
  91. 91.
    Araki M, Shinzaki S, Yamada T, et al. Age at onset is associated with the seasonal pattern of onset and exacerbation in inflammatory bowel disease. J Gastroenterol. 2017;52:1149–57.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Jakob Seidelin
    • 1
  • Johan Burisch
    • 2
  1. 1.Department of GastroenterologyHerlev University HospitalHerlevDenmark
  2. 2.Department of GastroenterologyNorth Zealand University HospitalFrederikssundDenmark

Personalised recommendations